Mumbai, MAHARASHTRA :

Synopsis

“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,000 employees who stand with Cipla, putting patients’ interests before their own and upholding our purpose of Caring for Life,” Hamied, executive vice-chairperson, Cipla, told ET.

Samina Hamied represents a rich legacy. Her grandfather, KA Hamied, a freedom fighter and nationalist, founded Cipla in 1935, making it one of India’s oldest pharmaceutical companies. Her uncle Yusuf Hamied is the doyen of Indian pharma known globally for making affordable generic AIDS drugs accessible to millions of patients in Africa and other low- and middle-income countries.

“I am humbled and honoured to receive the ET’s Businesswoman of the Year Award. This recognition belongs to each and every one of our 25,000 employees who stand with Cipla, putting patients’ interests before their own and upholding our purpose of Caring for Life,” Hamied, executive vice-chairperson, Cipla, told ET.

Hamied has successfully steered Cipla on an accelerated growth path with a focus on boosting margins, without diluting the core values it stood for.

Both as executive director from July 2015 and as executive vice-chairperson from September 2016, Hamied has been instrumental in driving the company’s transformation from a traditional low-cost drug manufacturer to one with a young professional management and an aggressive approach towards inorganic expansion. Under her, Cipla also restructured its business and has also initiated cost-optimisation measures.

She spearheaded Cipla’s entry into the US market with strategic acquisitions of two generic companies, InvaGen Pharma and Exelan Pharma, for $550 million in 2015.

From FY15 to FY21, Cipla’s US revenue grew close to five times. US business contributed one-fifth of the total revenue in FY21.

Cipla’s revenue from operations grew at a compounded annual growth rate of 7% in the last 5 years to Rs 19,160 crore in FY21. Ebitda margin and net profit rose 12% CAGR in the last 5 years to 22.5% and Rs 2,405 crore, respectively, in FY21.

During Covid, Cipla launched antivirals, antibody cocktails, testing kits, masks and sanitizers. Cipla’s India business grew 15% year-on-year to Rs 7,736 crore.

Hamied focuses on board and governance issues, furthering Cipla’s global partnerships, shaping its corporate culture and hiring the right talent.

source: http://www.economictimes.indiatimes.com / The Economic Times / Home> English edition> Business News> Industry> Healthcare-Biotech> Healthcare / by ET Bureau / March 28th, 2022